Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2022-05-12 00:00:00 ET · period of report 2022-05-11 · accession 0001209191-22-028685 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-12 | 2022-05-11 | TVTX | Baynes Roy D. | Dir | A - Grant | $0.00 | +3,000 | 20.0K | +18% | $0 |
| D | 2022-05-12 | 2022-05-11 | TVTX | Baynes Roy D. | Dir | A - Grant | $0.00 | +9,000 | 9,000 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-11 | A | A | 3,000 | $0.00 | 20,000 | D | — | — | (F1) Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. (F2) The equity award vests over a one year period. |
| 2 | Derivative | Stock option (right to buy) | 2022-05-11 | A | A | 9,000 | $0.00 | 9,000 | D | $21.38 · 2023-05-11 to 2032-05-10 | 9,000 Common Stock | (F1) Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. (F2) The equity award vests over a one year period. |